Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 23.2.2015 | EN | Official Journal of the European Union | C 65/49 |

---

Action brought on 22 December 2014 — Alnapharm v OHIM — Novartis (Alrexil)

(Case T-839/14)

(2015/C 065/66)

Language in which the application was lodged: English

Parties

Applicant: Alnapharm GmbH & Co. KG (Hamburg, Germany) (represented by: H. Heldt, lawyer)

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM)

Other party to the proceedings before the Board of Appeal: Novartis AG (Basel, Switzerland)

Details of the proceedings before OHIM

Applicant: The other party to the proceedings before the Board of Appeal

Trade mark at issue: Community word mark ‘Alrexil’ — Application for registration No 10 306 249

Procedure before OHIM: Opposition proceedings

Contested decision: Decision of the Fourth Board of Appeal of OHIM of 23 October 2014 in Case R 1723/2013-4

Form of order sought

The applicant claims that the Court should:

|  |  |
| --- | --- |
| — | annul the contested decision and refer the case back to the Board of Appeal of OHIM; |

|  |  |
| --- | --- |
| — | order OHIM to pay the costs. |

Plea in law

|  |  |
| --- | --- |
| — | Infringement of Article 8(1)(b) of Regulation No 207/2009. |

---

[Top](#document1)